Navigation Links
GENova Bio ends relationship with Bridge BioResearch
Date:9/18/2009

NEW YORK, NY, Sept. 18 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova") today announced that it has ceased the relationship with Bridge BioResearch PLC and unconditionally retract the announcement made earlier this month and GENova further announced that Mr. Anders Bogh Jensen, Chief Science Officer of Bridge BioResearch PLC, will not be serving on the GENova's Scientific Advisory Board.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these drug product candidates to Big Pharmaceutical and Biotechnology companies. Visit GENova online at www.genovabio.com.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. GENova Biotherapeutics signs LOI with Korean university for stem cell research and patents sharing
2. GENova Biotherapeutics secures new cancer drugs targets
3. GENova Biotherapeutics signs engagement agreement with PacificWave Partners Limited
4. GENova and TheraGlass in advanced negotiations
5. GENova Biotherapeutics forming academic partnerships
6. GENova Biotherapeutics signs collaboration agreement with Prime BioResearch
7. GENova Biotherapeutics and Prime BioResearch signs LOI on diabetes and cancer cure
8. GENova gains access to Big Pharma
9. GENova appoints Dr. Wang Chong to Scientific Advisory Board
10. GENova appoints Dr. Philip Gould to Scientific Advisory Board
11. GENova issues clarifying press release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... “Beyond and Back”: a true-life testimony of tragedy ... of published author Bonetta Rose, a wife, mother and grandmother committed to sharing her ... Faith Publishing, Bonetta Rose‘s new book presents actual events in the life of her ...
(Date:3/23/2017)... ... 2017 , ... “The Trainer”: an electrifying and suspenseful gunslinger novel with ... with an active imagination and an enthusiasm for action and adventure stories. ... Bill Hart, who sat looking at the thirty-three notches that lined the edges of ...
(Date:3/22/2017)... ... March 23, 2017 , ... ... solutions for drugs, biologics and consumer health products, today announced that it had ... currently taking place at the Suntec Singapore International Exhibition & Convention Centre, Singapore. ...
(Date:3/22/2017)... Georgia (PRWEB) , ... March 22, 2017 , ... ... time consuming and frustrating and this tool bypasses that. Healthcare facilities across ... identified an opportunity to offer their clients and hospitals, across the country, an ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Rett ... a devastating neurological disorder that afflicts 350,000 individuals worldwide. Rett Syndrome is ... and almost exclusively strikes females. Following a normal infancy, Rett Syndrome takes ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , 22 de marzo de 2017   ... líder de soluciones de productos y servicios para ... que ha adquirido EPL Archives, Inc., una organización ... clientes en todo el ciclo de vida de ... una muestra de archivo, almacenamiento de documentos y ...
(Date:3/22/2017)... , March 22, 2017 Under ... Chinese pharmaceutical packaging market size increased year by ... From 2017 to 2021, the market size will ... is expected to outnumber RMB140 billion in 2021, ... the rapid development of biological agents and supporting ...
(Date:3/22/2017)... RADNOR, Pennsylvania , 22. März 2017 ... führende unabhängige und weltweit tätige Anbieter von ... gibt heute den Erwerb von EPL Archives ... biologischer Stoffe, der Kunden im kompletten Zyklus ... bei Verwahrung von Proben, Speicherung von Dokumenten ...
Breaking Medicine Technology: